220 related articles for article (PubMed ID: 27806715)
1. Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
Masarwah A; Auvinen P; Sudah M; Dabravolskaite V; Arponen O; Sutela A; Oikari S; Kosma VM; Vanninen R
BMC Cancer; 2016 Nov; 16(1):833. PubMed ID: 27806715
[TBL] [Abstract][Full Text] [Related]
2. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
4. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
[TBL] [Abstract][Full Text] [Related]
5. Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.
Green AR; Soria D; Powe DG; Nolan CC; Aleskandarany M; Szász MA; Tőkés AM; Ball GR; Garibaldi JM; Rakha EA; Kulka J; Ellis IO
Breast Cancer Res Treat; 2016 May; 157(1):65-75. PubMed ID: 27116185
[TBL] [Abstract][Full Text] [Related]
6. The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER
Mokbel K; Wazir U; Wazir A; Kasem A; Mokbel K
Anticancer Res; 2018 Aug; 38(8):4747-4752. PubMed ID: 30061244
[TBL] [Abstract][Full Text] [Related]
7. The reciprocal association between mammographic breast density, hyaluronan synthesis and patient outcome.
Masarwah A; Tammi M; Sudah M; Sutela A; Oikari S; Kosma VM; Tammi R; Vanninen R; Auvinen P
Breast Cancer Res Treat; 2015 Oct; 153(3):625-34. PubMed ID: 26362804
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C
Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854
[TBL] [Abstract][Full Text] [Related]
10. Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.
Serrero G; Hawkins DM; Bejarano PA; Ioffe O; Tkaczuk KR; Elliott RE; Head JF; Phillips J; Godwin AK; Weaver J; Hicks D; Yue B
Diagn Pathol; 2016 Aug; 11(1):71. PubMed ID: 27501955
[TBL] [Abstract][Full Text] [Related]
11. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
12. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
[TBL] [Abstract][Full Text] [Related]
13. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
Laas E; Mallon P; Duhoux FP; Hamidouche A; Rouzier R; Reyal F
PLoS One; 2016; 11(2):e0148957. PubMed ID: 26895349
[TBL] [Abstract][Full Text] [Related]
16. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
17. A molecular signature of the Nottingham prognostic index in breast cancer.
Yu K; Lee CH; Tan PH; Hong GS; Wee SB; Wong CY; Tan P
Cancer Res; 2004 May; 64(9):2962-8. PubMed ID: 15126326
[TBL] [Abstract][Full Text] [Related]
18. [The value of searching for additional prognostic factors in combination with Nottingham Prognostic Index in breast carcinoma patients].
Jakić-Razumović J; Corić M; Vrbanec D; Babić D; Hlupić L; Belev B
Lijec Vjesn; 2005; 127(1-2):3-7. PubMed ID: 16145866
[TBL] [Abstract][Full Text] [Related]
19. Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer.
Suen D; Chow LW
Biomed Pharmacother; 2006 Jul; 60(6):293-7. PubMed ID: 16828252
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
